PepGen climbs after $125 mln equity raise for muscle disease drug

By Reuters News

** Shares of PepGen PEPG.O up 6.5% at $5.60 premarket on Thurs after $125 mln follow-on priced

** PEPG late Weds sold 25 mln shares at $5

** On Tues, PEPG's stock surged 93% to $4.61, an over seven-month high, after stronger-than-expected mid-stage trial results for its experimental drug, PGN-EDODM1, for myotonic dystrophy type 1 (DM1)

** Stock closed up ~14% at $5.26 on Weds

** Co to use net offering proceeds to fund clinical development of PGN-EDODM1, and for working capital and other general purposes

** Leerink, Stifel and Guggenheim are joint bookrunners; Oppenheimer is a passive bookrunner

** Boston, Massachusetts-based PEPG has ~69.26 mln shares outstanding

** Through Weds, stock down 19% YTD

** 7 of 8 analysts rate the stock "strong buy" or "buy", 1 "hold"; median PT $11, per LSEG data

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.